Klivira
Request demo

Optimizing Pediatric Oncology OptumRx Integration for Expedited Care

Effective pediatric oncology OptumRx integration is critical for ensuring timely access to life-saving treatments, from complex chemotherapy regimens to advanced cellular therapies and radiation.

For revenue cycle directors and prior authorization coordinators in pediatric oncology, managing OptumRx prior authorizations presents unique challenges due to the high-cost, time-sensitive nature of treatments and the specific documentation required. Klivira's platform is engineered to streamline these workflows, reducing administrative burden and accelerating patient care pathways.

Navigating Pediatric Oncology Prior Authorization Complexities

Pediatric oncology involves highly specialized and often urgent treatment protocols, including multi-agent chemotherapy regimens, novel CAR-T cell therapies, and advanced radiation techniques like proton beam therapy. Each of these interventions frequently triggers prior authorization requirements with pharmacy benefit managers (PBMs) such as OptumRx, necessitating precise clinical documentation and adherence to evidence-based guidelines.

Key Prior Authorization Triggers for OptumRx in Pediatric Oncology

  • High-cost chemotherapy regimens, particularly those guided by COG (Children's Oncology Group) protocols.
  • CAR-T cell therapies (e.g., tisagenlecleucel, brexucabtagene autoleucel) and other cellular immunotherapies.
  • Proton beam therapy for specific tumor types and locations.
  • Advanced diagnostic imaging (e.g., PET/CT, high-resolution MRI) for staging, restaging, and treatment response assessment.
  • Specialty medications for supportive care, antiemetics, and growth factors, often dispensed through OptumRx specialty pharmacy.

Streamlining EMR and Payer Touchpoints for OptumRx Submissions

Effective integration requires seamless data exchange between your EMR (e.g., Epic, Cerner) and OptumRx. Klivira facilitates this by automating the extraction of relevant clinical data, such as treatment plans, lab results, and imaging reports, directly from your EMR. This data is then formatted for efficient submission via OptumRx's ePA portal or X12 278 transactions, minimizing manual data entry and potential errors.

Evidence-Based PA: Adhering to Clinical Guidelines

Prior authorization for pediatric oncology treatments is heavily informed by established clinical guidelines. Klivira's platform integrates decision support that aligns with recommendations from bodies like the Children's Oncology Group (COG), National Comprehensive Cancer Network (NCCN), and American Society of Clinical Oncology (ASCO). This ensures submitted documentation substantiates medical necessity according to payer-accepted evidence, reducing denials.

Klivira's Impact on Pediatric Oncology PA Workflows

By automating the OptumRx prior authorization process, Klivira empowers pediatric oncology teams to focus on patient care rather than administrative tasks. Our platform helps accelerate approval times for critical therapies, reduce denial rates, and improve overall revenue cycle efficiency, directly impacting patient outcomes and financial health for your institution.

Frequently asked questions

How does Klivira handle specific OptumRx documentation requirements for pediatric oncology?

Klivira's platform is configured to identify and extract the precise clinical notes, lab results, imaging reports, and treatment protocols (e.g., COG) required by OptumRx for pediatric oncology submissions. We ensure all necessary elements are present and correctly formatted before submission, aligning with payer-specific rules and medical policies.

Can Klivira integrate with our EMR to pull pediatric oncology patient data for OptumRx submissions?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR and custom API connections, to securely pull relevant patient data. This enables automated population of prior authorization forms for OptumRx, reducing manual transcription and ensuring data accuracy for pediatric oncology cases.

What types of pediatric oncology treatments typically require OptumRx prior authorization through Klivira?

Klivira automates PA for high-cost pediatric oncology treatments such as specific chemotherapy regimens, CAR-T cell therapies, proton beam therapy, and specialty pharmacy medications. Our system identifies when an OptumRx PA is needed based on your EMR's order entry and payer rules.

How does Klivira support urgent prior authorizations common in pediatric oncology?

Klivira's platform is designed with expedited workflows and real-time status updates to support urgent PA requests. By automating the submission and tracking process for OptumRx, we help accelerate approval times, which is critical for time-sensitive pediatric oncology treatments.

Does Klivira's platform help with appeals for OptumRx pediatric oncology denials?

Yes, Klivira provides tools to manage and streamline the appeals process for OptumRx denials. Our system retains all submitted documentation and tracks denial reasons, enabling your team to efficiently gather additional information and submit comprehensive appeals for pediatric oncology cases.

Related coverage

Other pediatric-oncology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo